Julian Taugner
About
Julian Taugner is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Julian Taugner has authored 34 papers receiving a total of 299 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Julian Taugner's work include Lung Cancer Diagnosis and Treatment (23 papers), Lung Cancer Treatments and Mutations (21 papers) and Lung Cancer Research Studies (11 papers). Julian Taugner is often cited by papers focused on Lung Cancer Diagnosis and Treatment (23 papers), Lung Cancer Treatments and Mutations (21 papers) and Lung Cancer Research Studies (11 papers). Julian Taugner collaborates with scholars based in Germany and Netherlands. Julian Taugner's co-authors include Chukwuka Eze, Farkhad Manapov, Claus Belka, Lukas Käsmann, Amanda Tufman, Olarn Roengvoraphoj, Niels Reinmuth, Thomas Duell, Minglun Li and Nina-Sophie Schmidt-Hegemann and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Physics in Medicine and Biology.
In The Last Decade
Julian Taugner
29 papers receiving 298 citations
Peers
Julian Taugner
Luxi Ye China
M. Neubauer United States
Chiara Reverberi Italy
Britta Lödén Sweden
Martin Kimmich Germany
C. Garcia Belgium
Gwendolyn H.M.J. Griffioen Netherlands
Jean-Baptiste Paoli United States
Melline G.M. Schilham Netherlands
Conrad‐Amadeus Voltin Germany
Citations per year, relative to Julian Taugner Julian Taugner (= 1×)
peers
Luxi Ye
Countries citing papers authored by Julian Taugner
Since
Specialization
Citations
This map shows the geographic impact of Julian Taugner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julian Taugner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julian Taugner more than expected).
Fields of papers citing papers by Julian Taugner
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Julian Taugner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julian Taugner. The network helps show where Julian Taugner may publish in the future.
Co-authorship network of co-authors of Julian Taugner
This figure shows the co-authorship network connecting the top 25 collaborators of Julian Taugner. A scholar is included among the top collaborators of Julian Taugner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julian Taugner. Julian Taugner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Eze, Chukwuka, Daniela Thorwarth, Julian Taugner, et al.. (2025). Deep learning-based contour propagation in magnetic resonance imaging-guided radiotherapy of lung cancer patients. Physics in Medicine and Biology. 70(14). 145018–145018.
2.
Taugner, Julian, Lukas Käsmann, Nina-Sophie Schmidt-Hegemann, et al.. (2024). Dosimetric Predictors of Acute Radiation Pneumonitis and Esophagitis in Hypofractionated Thoracic Irradiation of Non-Small Cell Lung Cancer Patients With Poor Prognostic Factors. Advances in Radiation Oncology. 10(2). 101682–101682.
3.
Lehmann, Jöerg, Julian Taugner, Lukas Käsmann, et al.. (2023). EP08.02-15 Moderately Hypofractionated PET/CT-Based Thoracic Radiotherapy in Elderly and Multimorbid Patients with Stage II/III NSCLC. Journal of Thoracic Oncology. 18(11). S575–S576.
4.
Käsmann, Lukas, Chukwuka Eze, Julian Taugner, et al.. (2023). Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study. Journal of Cancer Research and Clinical Oncology. 149(10). 7393–7403.
5.
Taugner, Julian, Lukas Käsmann, Amanda Tufman, et al.. (2022). Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis. Journal of Cancer Research and Clinical Oncology. 149(7). 3267–3276.
6.
Käsmann, Lukas, Julian Taugner, Chukwuka Eze, et al.. (2022). Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a prospective longitudinal biomarker study. Translational Lung Cancer Research. 11(7). 1503–1509.
7.
Taugner, Julian, et al.. (2022). Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab. BMC Cancer. 22(1). 317–317.
8.
Käsmann, Lukas, et al.. (2021). Prognostic Role of Lung Immune Scores for Prediction of Survival in Limited-stage Small Cell Lung Cancer. In Vivo. 35(2). 929–935.
9.
Taugner, Julian, Lukas Käsmann, Chukwuka Eze, et al.. (2021). Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients. Investigational New Drugs. 39(4). 1189–1196.
10.
Taugner, Julian, Lukas Käsmann, Chukwuka Eze, et al.. (2021). Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition. Investigational New Drugs. 40(1). 163–171.
11.
Unterrainer, Marcus, Julian Taugner, Lukas Käsmann, et al.. (2021). Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition. European Journal of Nuclear Medicine and Molecular Imaging. 49(4). 1407–1416.
12.
Käsmann, Lukas, Chukwuka Eze, Julian Taugner, et al.. (2020). Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy. Radiation Oncology. 15(1). 167–167.
13.
Hoffmann, Michael M., D. Reitz, Julian Taugner, et al.. (2020). Blood Parameters Demonstrating a Significant Survival Impact in Patients With Locally Advanced NSCLC Undergoing Definitive Chemoradiotherapy. Anticancer Research. 40(4). 2319–2322.
14.
Käsmann, Lukas, Chukwuka Eze, Julian Taugner, et al.. (2020). External Validation of a Survival Score for Limited-Stage Small Cell Lung Cancer Patients Treated with Chemoradiotherapy. Lung. 198(1). 201–206.
15.
Roengvoraphoj, Olarn, Lukas Käsmann, Chukwuka Eze, et al.. (2020). Maximum standardized uptake value of primary tumor (SUVmax_PT) and horizontal range between two most distant PET-positive lymph nodes predict patient outcome in inoperable stage III NSCLC patients after chemoradiotherapy. Translational Lung Cancer Research. 9(3). 541–548.
16.
Käsmann, Lukas, Julian Taugner, Chukwuka Eze, et al.. (2020). Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Radiation Oncology. 15(1). 5–5.
17.
Käsmann, Lukas, Julian Taugner, Chukwuka Eze, et al.. (2019). Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment. Anticancer Research. 39(9). 5077–5081.
18.
Eze, Chukwuka, Julian Taugner, Olarn Roengvoraphoj, et al.. (2019). Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis. Radiation Oncology. 14(1). 163–163.
19.
Roengvoraphoj, Olarn, Chukwuka Eze, Julian Taugner, et al.. (2018). How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience. European Journal of Nuclear Medicine and Molecular Imaging. 45(12). 2103–2109.
20.
Roengvoraphoj, Olarn, Chukwuka Eze, Minglun Li, et al.. (2017). Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer. Strahlentherapie und Onkologie. 194(2). 107–115.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Luxi Ye Breakdown of academic impact, for papers by M. Neubauer Breakdown of academic impact, for papers by Chiara Reverberi Breakdown of academic impact, for papers by Britta Lödén Breakdown of academic impact, for papers by Martin Kimmich Breakdown of academic impact, for papers by C. Garcia Breakdown of academic impact, for papers by Gwendolyn H.M.J. Griffioen Breakdown of academic impact, for papers by Jean-Baptiste Paoli Breakdown of academic impact, for papers by Melline G.M. Schilham Breakdown of academic impact, for papers by Conrad‐Amadeus Voltin